We have recently proposed a model of “microRNA switch”, where the upregulation of miR-371a-3p in nonteratomatous GCT targets TP53, while across differentiation towards teratoma, miR-371a-3p is replaced by miR-885-5p, which is upregulated and activates TP53, possibly contributing to the differential response to cisplatin [40] (Figure 3). This evidence concerns the gene TP53 and teratoma.